Bavarian Nordic A/S/ DK0015998017 /
2024-07-26 4:59:39 PM | Chg. -4.10 | Volume | Bid5:10:00 PM | Ask5:10:00 PM | High | Low |
---|---|---|---|---|---|---|
181.00DKK | -2.22% | 219,334 Turnover: 35.14 mill. |
180.65Bid Size: 31 | 180.85Ask Size: 82 | 187.70 | 180.50 |
GlobeNewswire
06-26
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to...
GlobeNewswire
06-17
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
GlobeNewswire
05-31
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Sm...
GlobeNewswire
05-07
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
04-29
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chiku...
GlobeNewswire
03-20
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire
02-23
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines...
GlobeNewswire
2023-11-09
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
2023-09-21
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
2022-03-21
Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Com...
GlobeNewswire
2022-02-28
Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead...
GlobeNewswire
2022-02-14
Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Pre...
GlobeNewswire
2022-02-03
Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 Guidance